135 related articles for article (PubMed ID: 37388759)
21. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
[TBL] [Abstract][Full Text] [Related]
22. Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA; Hofmann C; Lott D; Gieschke R; Klein G; Boess F; Grimm HP; Kerchner GA; Baudler-Klein M; Smith J; Doody RS;
Alzheimers Dement; 2023 Jun; 19(6):2287-2297. PubMed ID: 36454709
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
Mattsson-Carlgren N; Janelidze S; Palmqvist S; Cullen N; Svenningsson AL; Strandberg O; Mengel D; Walsh DM; Stomrud E; Dage JL; Hansson O
Brain; 2020 Dec; 143(11):3234-3241. PubMed ID: 33068398
[TBL] [Abstract][Full Text] [Related]
24. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
[TBL] [Abstract][Full Text] [Related]
25. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
[TBL] [Abstract][Full Text] [Related]
26. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
27. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
28. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
29. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
30. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
Pereira JB; Janelidze S; Stomrud E; Palmqvist S; van Westen D; Dage JL; Mattsson-Carlgren N; Hansson O
Brain; 2021 Oct; 144(9):2826-2836. PubMed ID: 34077494
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
34. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.
Milà-Alomà M; Ashton NJ; Shekari M; Salvadó G; Ortiz-Romero P; Montoliu-Gaya L; Benedet AL; Karikari TK; Lantero-Rodriguez J; Vanmechelen E; Day TA; González-Escalante A; Sánchez-Benavides G; Minguillon C; Fauria K; Molinuevo JL; Dage JL; Zetterberg H; Gispert JD; Suárez-Calvet M; Blennow K
Nat Med; 2022 Sep; 28(9):1797-1801. PubMed ID: 35953717
[TBL] [Abstract][Full Text] [Related]
35. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe SL; Willis BA; Hawdon A; Natanegara F; Chua L; Foster J; Shcherbinin S; Ardayfio P; Sims JR
Alzheimers Dement (N Y); 2021; 7(1):e12112. PubMed ID: 33614890
[TBL] [Abstract][Full Text] [Related]
36. P-tau217 in Alzheimer's disease.
Telser J; Risch L; Saely CH; Grossmann K; Werner P
Clin Chim Acta; 2022 Jun; 531():100-111. PubMed ID: 35341762
[TBL] [Abstract][Full Text] [Related]
37. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.
Hall S; Janelidze S; Londos E; Leuzy A; Stomrud E; Dage JL; Hansson O
Mov Disord; 2021 Mar; 36(3):767-771. PubMed ID: 33285015
[TBL] [Abstract][Full Text] [Related]
38. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
40. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.
Doré V; Doecke JD; Saad ZS; Triana-Baltzer G; Slemmon R; Krishnadas N; Bourgeat P; Huang K; Burnham S; Fowler C; Rainey-Smith SR; Bush AI; Ward L; Robertson J; Martins RN; Masters CL; Villemagne VL; Fripp J; Kolb HC; Rowe CC
Alzheimers Dement (Amst); 2022; 14(1):e12307. PubMed ID: 35415202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
